The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Learn more about what to expect if you’ve been prescribed this weight loss medication to help treat this chronic liver condition.

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural gut hormone, providing a new approach for managing type 2 diabetes and ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. What Happens If You Use Expired Semaglutide? Wondering what happens if you use expired semaglutide?

Getting to grips with rising diabetes rates is arguably one of the most urgent tasks for South Africa's public healthcare system, but the setbacks keep coming. While some communities are facing ...

Weight-loss drug semaglutide, also used to treat type-2 diabetes, will face its next big turning point in early 2026, when patents held by Novo Nordisk expire in India. The Danish company sells the ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Elaine Chen covers biotech, co-writes The Readout newsletter, and ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner, Innovent, has bested Novo Nordisk’s reigning GLP-1 semaglutide, in a phase 3 study across both blood ...

The cardiovascular benefits of semaglutide (Wegovy; Novo Nordisk) seem to be independent of both baseline patient adiposity and subsequent weight loss with treatment, suggesting that the glucagon-like ...

The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, ...